Velcade, Novel Anticancer Treatment, Now Available Under NHI Coverage
Published: 2005-02-03 06:56:00
Updated: 2005-02-03 06:56:00
Janssen Korea announced this week that the company has completed the registration of Velcade (bortezomib) injection, a novel anticancer treatment, to the National Health Insurance (NHI) list of approved medications, and is now available in the domestic market starting February.
Regarded as ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
